RedHill’s Opaganib Gains Rare Pediatric Disease Designation, Unlocking PRV and $3.5B Market
RDHL•FDA grants RedHill’s opaganib rare pediatric disease designation for neuroblastoma, adding to its orphan drug status and unlocking a Priority Review Voucher, PDUFA fee waiver, tax credits and seven-year exclusivity. Preclinical data showed opaganib destabilizes n-Myc in high-risk neuroblastoma models; market projected at $3.5 billion by 2032.
1. Rare Pediatric Disease Designation
The FDA awarded opaganib rare pediatric disease designation for neuroblastoma in addition to its existing orphan drug status. This grants RedHill a Priority Review Voucher, PDUFA fee waiver, tax credits and, if approved, seven years of marketing exclusivity, expediting development and review timelines.
2. Preclinical Data Highlights
New preclinical findings presented at a major cancer research meeting demonstrated that opaganib added to chemotherapy destabilizes the oncogenic driver n-Myc via increased ceramide production, enhancing programmed cell death in high-risk neuroblastoma and triple-negative breast cancer models.
3. Market Potential and Pipeline Development
The neuroblastoma market is forecast to reach approximately $3.5 billion by 2032. Opaganib, a first-in-class oral SPHK2 inhibitor with established safety and efficacy profiles, is also being developed across multiple oncology, viral, inflammatory and metabolic indications through academic and government collaborations.
